THE HALLMARKS OF NEURODEGENERATION.
Discover IBL’s broad range of solutions optimised for neurodegeneration biomarkers measurement, designed to keep your research at the forefront of the latest trends in the field.
Neurodegeneration or neurodegenerative diseases are a group of disorders that are characterised by progressive loss of structure and function of neurons, including their death.
Most known neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis and Amyotrophic Lateral Sclerosis. Yet, research in the field of neurodegeneration elucidates many more often overlapping diseases that have similar cellular and sub-cellular pathogenic mechanisms.
Usually, the neurodegenerative diseases can be characterised by specific patterns of misfolded proteins, as shown in Figure 1. As a consequence, research is focusing on measuring these proteins in the different body fluids.
Involvement of different prion-like proteins in multiple neurodegenerative disorders. The figure depicts the overlapping pathological profile of Prion Protein (PrP, pink circle), α-Synuclein (blue circle), Amyloid-β (Aβ, orange circle), Tau (green circle), and TDP43 (yellow circle). Each of the stated disorders have further clinical variants (as shown in the case of AD), thereby complicating the role of prion-like proteins in bringing about the observed pathology. PDD: Parkinson’s disease with dementia; DS: Down’s syndrome; FTD-T: frontotemporal dementia with tau pathology; fAD—familial AD; sAD—sporadic AD; rpAD—rapidly-progressive AD; PCA-AD—posterior cortical atrophy–AD; PPA-AD—primary progressive aphasia with AD.1
Figure 1.
MEASURING NEURONAL BIOMARKERS IN BLOOD.
As CSF has disadvantages in sampling and not all patients do receive a lumbar puncture (e.g. PD, LBD… patients) studies have shown the usefulness of measuring certain biomarkers also in blood.
Boost your blood plasma data.
Easily eliminate inhibiting matrix effects and enrich your target by immunoprecipitation using IBL’s NEURO IP product portfolio provided by Roboscreen for total TAU, p50Tau, brain derived TAU, beta-Amyloid, and pathooligomeric alpha-Synuclein, enhancing the performance of your downstream assay of choice. The downstream analysis can then be any type of assay system, such as the Roche Elecsys®, the Mesoscale QuickPlex, Quanterix SIMOA®, Fujirebio Lumipulse® or even any type of ELISA.
Figure 2: Overview of different biomarkers for neurodegenerative diseases and respective sample types, where they have been measured already. Adapted from O. Hansson.2
IBL’s comprehensive suite of innovative biomarker measurement tools are tailored for neurodegenerative research, with a strong focus on diseases like Alzheimer’s, Parkinson’s, ALS and frontotemporal dementia. Some of their key products are:
- Amyloid-beta (Aβ 1-40 and 1-42)
- Total Tau and Phospho-Tau
- Neurofilament Light Chain (NF-L)
- α-Synuclein
- TDP-43
References:
- Noor A. et al. Neurodegenerative Proteinopathies in the Proteoform Spectrum-Tools and Challenges. Int J Mol Sci. 2021;22(3):1085.
- Hansson, O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963.
* Not all products are included on the Australian Register of Therapeutic Goods (ARTG), please contact Abacus dx to check on regulatory.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
